Total Payments
$752,333
2024 Payments
$6,090
Companies
48
Transactions
852
Medicare Patients
647
Medicare Billing
$39,960
Payment Breakdown by Category
Consulting$376,644 (50.1%)
Research$254,283 (33.8%)
Other$59,817 (8.0%)
Travel$43,022 (5.7%)
Food & Beverage$18,256 (2.4%)
Education$309.58 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $376,644 | 119 | 50.1% |
| Unspecified | $254,283 | 128 | 33.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $51,557 | 48 | 6.9% |
| Travel and Lodging | $43,022 | 94 | 5.7% |
| Food and Beverage | $18,256 | 452 | 2.4% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $5,760 | 2 | 0.8% |
| Honoraria | $2,500 | 1 | 0.3% |
| Education | $309.58 | 8 | 0.0% |
Payments by Type
General
$498,050
724 transactions
Research
$254,283
128 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bausch Health US, LLC | $116,340 | 9 | $0 (2019) |
| GENZYME CORPORATION | $65,595 | 35 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $56,568 | 52 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $55,945 | 56 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $52,016 | 66 | $0 (2024) |
| Eli Lilly and Company | $50,401 | 23 | $0 (2024) |
| LEO Pharma Inc. | $42,523 | 27 | $0 (2023) |
| Regeneron Pharmaceuticals, Inc. | $42,108 | 55 | $0 (2022) |
| Lilly USA, LLC | $40,781 | 71 | $0 (2023) |
| Janssen Biotech, Inc. | $38,761 | 51 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,090 | 59 | Eli Lilly and Company ($1,705) |
| 2023 | $27,335 | 80 | Novartis Pharmaceuticals Corporation ($8,617) |
| 2022 | $27,986 | 84 | LEO Pharma Inc. ($7,657) |
| 2021 | $66,224 | 77 | LEO Pharma Inc. ($15,059) |
| 2020 | $75,205 | 57 | E.R. Squibb & Sons, L.L.C. ($21,000) |
| 2019 | $152,484 | 183 | Bausch Health US, LLC ($23,400) |
| 2018 | $270,873 | 167 | Bausch Health US, LLC ($92,940) |
| 2017 | $126,136 | 145 | Lilly USA, LLC ($27,583) |
All Payment Transactions
852 individual payment records from CMS Open Payments — Page 1 of 35
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $15.10 | General |
| 12/04/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3.56 | General |
| 11/26/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: DERMATOLOGY | ||||||
| 11/21/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,250.00 | General |
| Category: Immunology | ||||||
| 11/19/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $23.51 | General |
| Category: DERMATOLOGY | ||||||
| 11/04/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $20.30 | General |
| 09/27/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $12.22 | General |
| 09/18/2024 | Eli Lilly and Company | TALTZ (Drug) | — | In-kind items and services | $104.58 | Research |
| Study: EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) • Category: Immunology | ||||||
| 09/17/2024 | Biofrontera Inc. | AMELUZ (Drug), BF-RhodoLED, XEPI | Food and Beverage | Cash or cash equivalent | $106.16 | General |
| Category: DERMATOLOGY | ||||||
| 09/17/2024 | Biofrontera Inc. | AMELUZ (Drug), BF-RhodoLED, XEPI | Food and Beverage | Cash or cash equivalent | $98.76 | General |
| Category: DERMATOLOGY | ||||||
| 09/17/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $20.96 | General |
| Category: IMMUNOLOGY | ||||||
| 09/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $0.42 | General |
| Category: IMMUNOLOGY | ||||||
| 09/14/2024 | ABBVIE INC. | — | — | In-kind items and services | $446.96 | Research |
| Study: A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa | ||||||
| 09/14/2024 | ABBVIE INC. | — | — | In-kind items and services | $64.99 | Research |
| Study: A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa | ||||||
| 09/14/2024 | ABBVIE INC. | — | — | In-kind items and services | $45.06 | Research |
| Study: A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa | ||||||
| 09/14/2024 | ABBVIE INC. | — | — | In-kind items and services | $18.53 | Research |
| Study: A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa | ||||||
| 09/13/2024 | ABBVIE INC. | — | — | In-kind items and services | $245.37 | Research |
| Study: A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa | ||||||
| 09/13/2024 | ABBVIE INC. | — | — | In-kind items and services | $111.56 | Research |
| Study: A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa | ||||||
| 09/13/2024 | ABBVIE INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa | ||||||
| 09/13/2024 | ABBVIE INC. | — | — | In-kind items and services | $15.50 | Research |
| Study: A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa | ||||||
| 09/13/2024 | ABBVIE INC. | — | — | In-kind items and services | $15.50 | Research |
| Study: A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa | ||||||
| 09/03/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $21.00 | General |
| 08/28/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $13.07 | General |
| Category: DERMATOLOGY | ||||||
| 08/21/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $83.58 | General |
| Category: Immunology | ||||||
| 08/01/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $36.48 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLECONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | Bausch Health US, LLC | $116,340 | 9 |
| MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF IXEKIZUMAB IN PATIENTS FROM 6 TO LESS THAN 18 YEARS OF AGE WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $19,291 | 5 |
| A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis | E.R. Squibb & Sons, L.L.C. | $16,250 | 2 |
| DUPIXENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $11,375 | 13 |
| A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Mod | E.R. Squibb & Sons, L.L.C. | $7,500 | 1 |
| A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $7,396 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA | Eli Lilly and Company | $6,466 | 3 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $6,044 | 3 |
| A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis | E.R. Squibb & Sons, L.L.C. | $5,500 | 1 |
| Phase III Study Psoriasis | E.R. Squibb & Sons, L.L.C. | $5,000 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $4,840 | 4 |
| A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris | Valeant Pharmaceuticals North America LLC | $4,050 | 2 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $3,808 | 5 |
| A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $3,705 | 7 |
| A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients 12 to 18 Years of Age, With Moderate-to-severe Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $3,207 | 12 |
| A randomized, double blind, vehicle-co ntrolled multicenter phase III study to evaluate the safety and efficacy of BF-200 ALA (Ameluz) and BF-RhodoLED in the treatment of superficial basal cell carcinoma (sBCC) with photodynamic therapy (PDT). | Biofrontera Inc. | $3,097 | 5 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $3,058 | 4 |
| A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study With Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis | E.R. Squibb & Sons, L.L.C. | $3,000 | 1 |
| A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to | E.R. Squibb & Sons, L.L.C. | $3,000 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $2,663 | 2 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLECONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | Valeant Pharmaceuticals North America LLC | $2,500 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY IN PATIENTS >=12 TO <18 YEARS OF AGE, WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $2,396 | 1 |
| A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) | AbbVie Inc. | $1,934 | 9 |
| Design, Validation and Scoring of the Atopic Dermatitis Control Tool (ADCT) | SANOFI-AVENTIS U.S. LLC | $1,664 | 1 |
| A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $1,542 | 1 |
| A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy | AbbVie Inc. | $1,449 | 7 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3375880 IN ADULT SUBJECTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: THE ADMIRE STUDY | Eli Lilly and Company | $1,423 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONG-TERM SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $1,412 | 4 |
| A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $1,054 | 4 |
| A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa | ABBVIE INC. | $988.47 | 9 |
| LIBERTY-AD CHRONOS | SANOFI-AVENTIS U.S. LLC | $865.00 | 1 |
| CC-10004-PSA-002 CC-10004-PSA-003 CC-10004-PSA-004 CC-10004-PSOR-008 CC-10004-PSOR-009 | Celgene Corporation | $417.00 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis | SANOFI-AVENTIS U.S. LLC | $313.14 | 1 |
| AN EXPLORATORY RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP MULTICENTER STUDY TO EXPLORE THE MODULATION OF INFLAMMATION IN THE SKIN CUTANEOUS ADIPOSE TISSUE AND BLOOD ENDOTHELIAL CELL INTERFACE BY COSENTYX SECUKINUMAB VERSUS PLACEBO IN MODERATE TO SEVERE PLAQUE PSORIASIS PATIENTS ADIPSO | Novartis Pharmaceuticals Corporation | $259.00 | 1 |
| A MULTICENTER STUDY WITH A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED WITHDRAWAL MAINTENANCE DOSING PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-1 | Eli Lilly and Company | $173.99 | 1 |
| RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | Eli Lilly and Company | $120.50 | 1 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | Eli Lilly and Company | $104.58 | 1 |
| A randomized, double blind, vehicle-co ntrolled multicenter phase III study to evaluate the safety and efficacy of BF-200 ALA (Amelux) and BF-RhodoLED in the treatment of superficial basal cell carcinoma (sBCC) with photodynamic therapy (PDT | Biofrontera Inc. | $77.88 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 137 | 172 | $19,022 | $7,628 |
| 2022 | 5 | 115 | 143 | $14,563 | $6,728 |
| 2021 | 6 | 190 | 239 | $28,039 | $13,535 |
| 2020 | 7 | 205 | 260 | $26,494 | $12,069 |
Total Patients
647
Total Services
814
Medicare Billing
$39,960
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 40 | 44 | $6,072 | $2,618 | 43.1% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 11 | 12 | $2,385 | $1,071 | 44.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 13 | 13 | $2,204 | $974.05 | 44.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 24 | 25 | $2,513 | $903.08 | 35.9% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 13 | 13 | $2,256 | $725.38 | 32.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 11 | 11 | $2,153 | $707.16 | 32.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 11 | 12 | $1,020 | $415.39 | 40.7% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 14 | 42 | $420.00 | $213.85 | 50.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 47 | 50 | $6,900 | $3,382 | 49.0% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 27 | 28 | $2,814 | $1,189 | 42.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 13 | 13 | $2,204 | $1,092 | 49.5% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 13 | 13 | $2,256 | $848.00 | 37.6% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 15 | 39 | $390.00 | $216.18 | 55.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 72 | 85 | $10,311 | $5,414 | 52.5% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 41 | 41 | $6,878 | $3,291 | 47.9% |
| 11104 | Punch biopsy of single skin lesion | Office | 2021 | 20 | 20 | $4,336 | $1,856 | 42.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 14 | 14 | $2,487 | $1,421 | 57.2% |
| 17000 | Destruction of skin growth | Office | 2021 | 28 | 32 | $3,288 | $1,305 | 39.7% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 15 | 47 | $740.00 | $246.64 | 33.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 49 | 58 | $6,090 | $3,366 | 55.3% |
| 99202 | New patient office or other outpatient visit, typically 20 minutes | Office | 2020 | 58 | 58 | $6,960 | $3,278 | 47.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 21 | 22 | $3,190 | $1,793 | 56.2% |
| 11104 | Punch biopsy of single skin lesion | Office | 2020 | 16 | 16 | $4,004 | $1,520 | 38.0% |
| 17000 | Destruction of skin growth | Office | 2020 | 32 | 33 | $3,465 | $1,345 | 38.8% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 12 | 13 | $1,105 | $482.56 | 43.7% |
About Dr. David Pariser, M.D
Dr. David Pariser, M.D is a Dermatology healthcare provider based in Norfolk, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1417050717.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Pariser, M.D has received a total of $752,333 in payments from pharmaceutical and medical device companies, with $6,090 received in 2024. These payments were reported across 852 transactions from 48 companies. The most common payment nature is "Consulting Fee" ($376,644).
As a Medicare-enrolled provider, Pariser has provided services to 647 Medicare beneficiaries, totaling 814 services with total Medicare billing of $39,960. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Other Specialties Dermatopathology
- Location Norfolk, VA
- Active Since 09/06/2006
- Last Updated 06/24/2024
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1417050717
Products in Payments
- DUPIXENT (Biological) $64,499
- DUPIXENT (Drug) $58,297
- COSENTYX (Biological) $40,570
- DUPIXENT DUPILUMAB INJECTION (Biological) $35,101
- TALTZ (Drug) $29,884
- Ameluz (Drug) $20,473
- REMICADE (Biological) $18,300
- Otezla (Drug) $16,696
- Tremfya (Drug) $15,619
- ENSTILAR (Drug) $14,245
- TREMFYA (Drug) $13,683
- COSENTYX (Drug) $7,522
- SILIQ (Drug) $7,464
- AMELUZ (Drug) $7,436
- Skyrizi (Biological) $5,242
- QBREXZA (Drug) $4,161
- Sotyktu (Drug) $3,898
- RINVOQ (Biological) $3,882
- EUCRISA (Drug) $3,511
- STELARA (Biological) $2,692
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Norfolk
Dr. Jonathan Schreiber, Md, MD
Dermatology — Payments: $282,069
Dermatology $282,069
Abby Van Voorhees, Md, MD
Dermatology — Payments: $94,620
Dermatology $94,620
Dr. Brian Johnson, Md, MD
Dermatology — Payments: $17,105
Dermatology $17,105
James Bota, Md, MD
Dermatology — Payments: $9,662
Dermatology $9,662
Katherine Belote, M.d, M.D
Dermatology — Payments: $5,895
Dermatology $5,895
Brian Johnson, Md, MD
Dermatology — Payments: $3,734
Dermatology $3,734